DANCANN PHARMA A/S |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0796 DKK | +10.56% |
|
+35.37% | +165.33% |
| Mar. 29 | Dancann Pharma Plans Up to DKK19 Million Rights Issue | MT |
| Feb. 28 | DanCann Pharma Notes Cannabis Legalization in Germany as Shares Surge | MT |
| Sales 2021 | 874K 126K | Sales 2022 | 7.19M 1.04M | Capitalization | 37.06M 5.35M |
|---|---|---|---|---|---|
| Net income 2021 | -11M -1.59M | Net income 2022 | -16M -2.31M | EV / Sales 2021 | 192 x |
| Net cash position 2021 | 7.74M 1.12M | Net cash position 2022 | 10.75M 1.55M | EV / Sales 2022 | 3.66 x |
| P/E ratio 2021 |
-12.7
x | P/E ratio 2022 |
-2.31
x | Employees | 10 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 14.49% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +10.56% | ||
| 1 week | +35.37% | ||
| Current month | +27.97% | ||
| 1 month | +100.00% | ||
| 3 months | +302.02% | ||
| 6 months | +32.67% | ||
| Current year | +165.33% |
1 week
0.04
0.13
1 month
0.020.13
Current year
0.010.13
1 year
0.010.56
3 years
0.017.06
5 years
0.017.06
10 years
0.017.06
| Managers | Title | Age | Since |
|---|---|---|---|
Jeppe Rasmussen
FOU | Founder | 29 | 18-03-19 |
| Director of Finance/CFO | 52 | 23-01-03 | |
| Chief Operating Officer | 37 | 22-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Carsten Trads
CHM | Chairman | 69 | - |
Tue Østergaard
BRD | Director/Board Member | 47 | 22-04-26 |
Jeppe Rasmussen
FOU | Founder | 29 | 18-03-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 0.0796 | +10.56% | 4 221 728 |
| 24-05-02 | 0.072 | +20.00% | 2,055,806 |
| 24-05-01 | 0.06 | -3.54% | 7,856,924 |
| 24-04-30 | 0.0622 | +3.67% | 1,644,218 |
| 24-04-29 | 0.06 | +7.14% | 2,322,272 |
End-of-day quote NORDIC GROWTH MARKET, May 02, 2024
More quotes
Dancann Pharma A/S is a Denmark-based pharmaceutical biotechnology company powered by cannabinoids. The Company is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma manufactures and distributes prescription drugs (Rx drugs) and over-the-counter drugs (OTCs), mainly focused on pain patients with alternative needs.
Calendar
2024-05-28
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +165.33% | 1.72M | |
| -1.43% | 103B | |
| +8.96% | 101B | |
| +4.40% | 23.07B | |
| -12.15% | 22.23B | |
| -4.36% | 18.05B | |
| -39.98% | 17.18B | |
| -10.04% | 16.94B | |
| +6.79% | 14.07B | |
| +38.61% | 12.35B |
- Stock Market
- Equities
- DANCAN Stock
